Selective induction of apoptosis in cancer cells by the ether lipid ET- 18-OCH3 (edelfosine): Molecular structure requirements, cellular uptake, and protection by bcl-2 and bcl-x(L)

Cancer Research

Volumn 57, Issue 7, 1997, Pages 1320-1328

  Mollinedo, Faustino ^a,c   Fernández Luna, Jose Luis ^b   Gajate, Consuelo ^a   Martín Martín, Belén ^a   Benito, Adalberto ^b   Martínez Dalmau, Rosa ^a   Modolell, Manuel ^b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EDELFOSINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; GENE EXPRESSION; GENES, BCL-2; HUMANS; LYMPHOCYTES; MICE; MONOCYTES; PHOSPHOLIPID ETHERS; PLATELET ACTIVATING FACTOR; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; SURAMIN; TUMOR CELLS, CULTURED;

EID: 1842290345     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Munder, P. G., and Westphal, O. Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem. Immunol., 49: 206-235, 1990.
2. 3. Biochem. Biophys. Res. Commun., 192: 603-609, 1993.
3. Houlihan, W., Lohmeyer, M., Workman, P., and Cheon, S. H. Phospholipid antitumor agents. Med. Res. Rev., 15: 157-223, 1995.
4. Andreesen, R., Modolell, M., Weltzien, H. U., Eibl, H., Common, H. H., Löhr, G. W., and Munder, P. G. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res., 38: 3894-3899, 1978.
5. Okamoto, S., Olson, A. C., Vogler, W. R., and Winton, E. F. Purging leukemic cells from stimulated human remission marrow with alkyl-lysophospholipid. Blood, 69: 1381-1387, 1987.
6. Dietzfelbinger, H. F., Kühn, D., Zafferani, M., Hanauske, A. R., Rastetter, J. W., and Berdel, W. E. Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation. Cancer Res., 53: 3747-3751, 1993.
7. Vogler, W. R., and Berdel, W. E. Autologous bone marrow transplantation with alkyl-lysophospholipid-purged marrow. J. Hematother., 2: 93-102, 1993.
8. Vogler, W. R. Bone marrow purging in acute leukemia with alkyl-lysophospholipids: a new family of anticancer drugs. Leukemia Lymphoma, 13: 53-60, 1994.
9. 3. Leuk. Res., 19: 417-425, 1995.
10. Koenigsmann, M. P., Notter, M., Knauf, W. U., Papadimitriou, C. A., Oberberg, D., Reufi, B., Mücke, C., Thiel, E., and Berdel, W. E. Chemopurging of peripheral blood-derived progenitor cells by alkyl-lysophospholipid and its effect on haematopoietic rescue after high-dose therapy. Bone Marrow Transplant., 75: 549-557, 1996.
11. von Mehren, M., Giantonio, B. J., McAleer, C., Schilder, R., McPhillips, J., and O'Dwyer, P. J. Phase I trial of ilmofosine as a 24 h infusion weekly. Invest. New Drugs, 13: 205-210, 1995.
12. Winkelmann, M., Ebeling, K., Strohmeyer, G., Hottenrott, G., Mechl, Z., Berges, W., Scholten, T., Westerhausen, M., Schlimok, G., and Sterz, R. Treatment results of the thioether lipid ilmofosine in patients with malignant tumours. J. Cancer Res. Clin. Oncol., 118: 405-407, 1992.
13. Diomede, L., Colotta, F., Piovani, B., Re, F., Modest, E. J., and Salmona, M. Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine: a possible basis for its selective action. Int. J. Cancer, 53: 124-130, 1993.
14. Diomede, L., Piovani, B., Re, F., Principe, P., Colotta, F., Modest, E. J., and Salmona, M. The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in human leukemic cells. Int. J. Cancer, 57: 645-649, 1994.
15. Mollinedo, F., Gajate, C., Tugores, A., Flores, I., and Naranjo, J. R. Differences in expression of transcription factor AP-1 in human promyelocytic HL-60 cells during differentiation towards macrophages versus granulocytes. Biochem. J., 294: 137-144, 1994.
16. Vaux, D. L., Cory, S., and Adams, J. Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (Lond.), 325: 440-442, 1988.
17. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 762: 156-159, 1987.
18. Feinberg, A. P., and Vogelstein, B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem., 132: 6-13, 1983.
19. Rothberg, P. G., Erisman, M. D., Diehl, R. E., Rovigatti, U. G., and Astrin, S. M. Structure and expression of the oncogene c-myc in fresh tumor material from patients with hematopoietic malignancies. Mol. Cell. Biochem., 4: 1096-1103, 1984.
20. L. Blood, 87: 3837-3843, 1996.
21. van Blitterswijk, W. J., van der Bend, R. L., Kramer, I. M., Verhoeven, A. J., Hilkmann, H., and de Widt, J. A metabolite of an antineoplastic ether phospholipid may inhibit transmembrane signalling via protein kinase C. Lipids, 22: 842-846, 1987.
22. Fleer, E. A. M., Unger, C., Kim, D-J., and Eibl, H. Metabolism of ether phospholipids and analogues in neoplastic cells. Lipids, 22: 856-861, 1987.
23. Honda, Z-I., Nakamura, M., Miki, I., Minami, M., Watanabe, T., Seyama, Y., Okado, H., Toh, H., Ito, K., Miyamoto, T., and Shimizu, T. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature (Lond.), 349: 342-346, 1991.
24. Vallari, D. S., Austinhirst, R., and Snyder, F. Development of specific functionally active receptors for platelet-activating factor in HL-60 cells following granulocytic differentiation (1990) J. Biol. Chem., 265: 4261-4265, 1990.
25. Ye, R. D., Prossnitz, E. R., Zou, A., and Cochrane, C. G. Characterization of a human cDNA that encodes a functional receptor for platelet activating factor. Biochem. Biophys. Res. Commun., 180: 105-111, 1991.
26. Müller, E., Dupuis, G., Turcotte, S., and Rola-Pleszczynski, M. Human PAF receptor gene expression: induction during HL-60 cell differentiation. Biochem. Biophys. Res. Commun., 181: 1580-1586, 1991.
27. Kunz, D., Gerard, N. P., and Gerard, C. The human leukocyte platelet-activating factor receptor. cDNA cloning, cell surface expression, and construction of a novel epitope-bearing analog. J. Biol. Chem., 267: 9101-9106, 1992.
28. Maudsley, D. J., and Morris, A. G. Rapid intracellular calcium changes in U937 monocyte cell line: transient increases in response to platelet-activating factor and chemotactic peptide but not interferon- or lipopolysaccharide. Immunology, 61: 189-194, 1987.
29. Carceller, E., Merlos, M., Giral, M., Almansa, C., Bartroli, J., Garcia-Rafanell, J., and Forn, J. Synthesis and structure-activity relationships of 1-acyl-4-((2-methyl-3-pyridyl-)cyanomethyl)piperazines as PAF antagonists. J. Med. Chem., 36: 2984-2997, 1993.
30. Heuer, H. O., Casals-Stenzel, J., Muacevic, G., and Weber, K-H. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. J. Pharmacol. Exp. Ther., 255: 962-9681990.
31. Williams, L. T., Tremble, P. M., Lavin, M. F., and Sunday, M. E. Platelet-derived growth factor receptors from high affinity state in membrane preparations. J. Biol. Chem., 259: 5287-5294, 1984.
32. Betsholtz, C., Johnsson, A., Heldin, C-H, and Westermark, B. Efficient reversion of simian sarcoma virus transformation and inhibition of growth factor mitogenesis by suramin. Proc. Natl. Acad. Sci. USA, 83: 6440-6444, 1986.
33. Coffey, R. J., Jr., Leof, E. B., Shipley, G. D., and Moses, H. L. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J. Cell. Physiol., 132: 143-148, 1987.
34. Yayon, A., and Klagsbrun, M. Autocrine transformation by chimeric signal peptide basic fibroblast growth factor: reversion by suramin. Proc. Natl. Acad. Sci. USA, 87: 5346-5350, 1990.
35. van der Bend, R. L., Brunner, J., Jalink, K., van Corven, E. J., Moolenaar, W. H., and van Blitterswijk, W. J. Identification of a putative membrane receptor for the bioactive phospholipid, lysophosphatidic acid. EMBO J., 11: 2495-2501, 1992.
36. Fortes, P. A. G., Ellory, J. C., and Lew, V. L. Suramin: a potent ATPase inhibitor which acts on the inside surface of the sodium pump. Biochim. Biophys. Acta, 318: 262-272, 1973.
37. Müller, W. E., and Wollert, W. Spectroscopic studies on the complex formation of suramin with bovine and human serum albumin. Biochim. Biophys. Acta, 427: 465-480, 1976.
38. Mollinedo, F., Gajate, C., and Modolell, M. The ether lipid 1-octadecyl-2-methylrac-glycero-3-phosphocholine induces expression of fos and jun proto-oncogenes and activates AP-1 transcription factor in human leukaemic cells. Biochem. J., 302: 325-329, 1994.
39. Vallari, D. S., Smith, Z. L., and Snyder, F. HL-60 cells become resistant towards antitumor ether-linked phospholipids following differentiation into a granulocytic form. Biochem. Biophys. Res. Commun., 156: 1-8, 1988.
40. Kelley, E. E., Modest, E. J., and Burns, C. P. Unidirectional membrane uptake of the ether lipid antineoplastic agent Edelfosine by L1210 cells. Biochem. Pharmacol., 45: 2435-2439, 1993.
41. Bazil, G. W., and Dexter, T. M. Role of endocytosis in the action of ether lipids on WEHI-3B, HL-60, and FDCP-mix A4 cells. Cancer Res., 50: 7505-7512, 1990.
42. Modolell, M., Andreesen, R., Pahlke, W., Brugger, U., and Munder, P. G. Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res., 39: 4681-4686, 1979.
43. Noseda, A., Godwin, P. L., and Modest, E. J. Effects of antineoplastic ether lipids on model and biological membranes. Biochim. Biophys. Acta, 945: 92-100, 1988.
44. Hoffman, D. R., Thomas, V. L., and Snyder, F. Inhibition of cellular transport systems by alkyl phospholipid analogs in HL-60 human leukemia cells. Biochim. Biophys. Acta, 1127: 74-80, 1992.
45. Boggs, K. P., Rock, C. O., and Jackowski, S. Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-racglycero-3-phosphocholine. J. Biol. Chem., 270: 11612-11618, 1995.
46. Nuñez, G., and Clarke, M. F. The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell Biol., 4: 399-403, 1994.
47. Yang, E., and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88: 386-401, 1996.
48. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., and Thompson, C. B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell. Cell, 74: 597-608, 1993.
49. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed ceil death. Cell, 74: 609-619, 1993.
50. Askew, D. S., Ashmun, R. A., Simmons, B. C., and Cleveland, J. L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene, 6: 1915-1922, 1991.
51. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
52. Shi, Y. Glynn, J. M., Guilbert, L. J., Cotter, T. G., Bissonnette, R. P., and Green, D. R. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science (Washington DC), 257: 212-214, 1992.
53. Bissonnette, R. P., Echeverry, F., Mahboubi, A., and Green, D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (Lond.), 359: 552-554, 1992.
54. Fanidi, A., Harrington, S. A., and Evan, G. I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature (Lond.), 559: 554-556, 1992.
55. Magistrelli, A., Villa, P., Benfenati, E., Modest, E. J., Salmona, M., and Tacconi, M. T. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OMe) in malignant cells, normal cells, and isolated and perfused rat liver. Drug Metab. Dispos., 23: 113-118, 1995.
56. Workman, P., Donaldson, J., and Lohmeyer, M. Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-Omethyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells. Biochem. Pharmacol., 41: 319-322, 1991.
57. Zoeller, R., Layne, M. D., and Modest, E. J. Animal cell mutants unable to take up biologically active glycerophospholipids. J. Lipid Res., 36: 1866-1875, 1995.
58. Andreesen, R., Modolell, M., Weltzien, H. U., and Munder, P. G. Alkyllysophospholipid induced suppression of human lymphocyte response to mitogens and selective killing of lymphoblasts. Immunobiology, 756: 498-508, 1979.
59. Klein-Franke, A., and Munder, P. G. Alkyllysophospholipid prevents induction of experimental allergic encephalomyelitis. J. Autoimmunity, 5: 83-91, 1992.
60. 3, displays long-lasting beneficial effect in chronic relapsing experimental encephalomyelitis in Lewis rat. Comparison with cyclosporin and (Val2)-dihydrocyclosporin effects in clinical, functional and histological studies. J. Autoimmunity, 5: 199-211, 1992.
61. Kovarik, J., Chabannes, D., and Borel, J. F. Immunoregulation and drug treatment in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Int. J. Immunopharmacol., 17: 255-263, 1995.
62. Hockenbery, D. M., Nunez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348: 334-336, 1990.
63. Garcia, I., Martinou, I., Tsujimoto, Y., and Martinou, J-C Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science (Washington DC), 258: 302-304, 1992.
64. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
65. Benito, A., Grillot, D., Nuñez, N., and Fernandez-Luna, J. L. Regulation of Bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. Am. J. Pathol., 146: 481-490, 1995.
66. Hockenbery, D. M., Oltvai, Z. N., Yin, X-M., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75: 241-251, 1993.
67. Berggren, M. I., Gallegos, A., Dressier, L. A., Modest, E. J., and Powis, G. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Cancer Res., 53: 4297-4302, 1993.